Skip to main content

Table 8 Wilcoxon sign-rank test was used to test the difference between pre-PP1M and Post-PP1M For Patients with ≥ 1 Inpatient Stay in Period A , Comparison of Direct Cost, Indirect Costs and Total Costs Before and After Transition to PP1M

From: A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China

  Direct costs Indirect costs Total costs
pre-PP1M (¥) 34,700±18,044 21,718±11,246 56,418±28,020
Post-PP1M (¥) 27,705±8266 15,023±10,875 42,728±15,307
Difference -20.16 -30.83% -24.27%
P < 0.01 < 0.01 0.478